Investors Urged to Join Class Action Against Altimmune, Inc. for Securities Fraud

Potential Class Action Lawsuit Against Altimmune, Inc.

On October 2, 2025, the Schall Law Firm, a prominent national shareholder rights litigation firm, highlighted a significant class action lawsuit against Altimmune, Inc. This lawsuit centers around alleged violations of the Securities Exchange Act of 1934, particularly focusing on sections 10(b) and 20(a), along with related SEC Rule 10b-5 protections.

Background of the Case

Altimmune, Inc., trading under the NASDAQ symbol ALT, has come under scrutiny following a troubling trend of false statements that misled investors. During the specified class period from August 10, 2023, to June 25, 2025, shareholders who faced losses are strongly encouraged to come forward and participate in the legal proceedings. The class action aims to hold the company accountable and seek restitution for the damages incurred by its investors.

The heart of the complaint focuses on the performance projections of Altimmune's drug candidate, Pemvidutide. Prior to the results from the IMPACT Phase 2B MASH trial, the company promoted Pemvidutide as a likely success. However, when the trial results became public, it was evident that the drug did not meet its primary endpoint—a failure that was downplayed by the company, which suggested optimism based on forthcoming Phase 3 trial results.

This disconnect between the company’s optimistic public statements and the actual outcomes is alleged to have caused unwarranted confusion and losses among investors when the truth emerged.

Call to Action for Investors

The Schall Law Firm is extending an invitation to all shareholders who purchased Altimmune securities during the class period to contact them before the deadline of October 6, 2025. Investors can reach out directly to Brian Schall at the firm's Los Angeles office, where consultations are offered at no charge to discuss their legal options. Warning is given that until the class action is certified, no representation by an attorney is guaranteed, making participation crucial for any affected shareholders.

The firm emphasizes that remaining an absent class member may prevent investors from recovering potential damages. The opportunity for shareholders to join the class could be a pivotal step in reclaiming the value lost due to the alleged misleading statements made by the company.

Details on Joining the Lawsuit

To participate, shareholders can visit the Schall Law Firm’s website or reach out via email. The firm specializes in representing investors in securities class actions, advocating for shareholder rights, and ensuring that firms are held accountable for fraudulent practices.

This case represents a critical juncture for Altimmune investors as they navigate the complexities of securities litigation. As further developments unfold, the Schall Law Firm will keep stakeholders informed, reinforcing their role in fighting for justice within the marketplace. Interested parties are advised to stay informed and act promptly as the deadline approaches.

The Schall Law Firm remains committed to transparency and ethics while handling cases of this nature, reminding the public of the importance of accurate corporate communications and the protection of investor rights.

Conclusion

As the case progresses, it is essential for affected Altimmune investors to stay engaged and take action. With the legal landscape continuously evolving, now is the time to reclaim control and hold Altimmune accountable for their alleged wrongdoing. Investors are reminded not to let this opportunity pass by to recover any losses incurred during the class period.

For more information, interested investors should conduct due diligence and consult with legal experts specializing in securities law. The Schall Law Firm is prepared to assist in this matter, seeking to provide each investor the guidance necessary to navigate this legal challenge.